For: | Zhang MH, Yuan YF, Liu LJ, Wei YX, Yin WY, Zheng LZY, Tang YY, Lv Z, Zhu F. Dysregulated microRNAs as a biomarker for diagnosis and prognosis of hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol 2023; 29(31): 4706-4735 [PMID: 37664153 DOI: 10.3748/wjg.v29.i31.4706] |
---|---|
URL: | https://www.wjgnet.com/1948-5204/full/v29/i31/4706.htm |
Number | Citing Articles |
1 |
Adane Adugna, Yalew Muche, Abateneh Melkamu, Mohammed Jemal, Habtamu Belew, Gashaw Azanaw Amare. Current updates on the molecular and genetic signals as diagnostic and therapeutic targets for hepatitis B virus-associated hepatic malignancy. Heliyon 2024; 10(14): e34288 doi: 10.1016/j.heliyon.2024.e34288
|
2 |
Shijie Wang, Ying Xie, Fufei Liu, Jianrong Wang, Yinghao Yang, Junxue Wang, Yongxiang Wang, Xiaofeng Hang. miR-3188 inhibits hepatitis B virus transcription by targeting Bcl-2. Archives of Virology 2024; 169(5) doi: 10.1007/s00705-024-05992-x
|
3 |
Han Liang, Junqiu Jiang, Feng Ren. Relationship Between Serum HBV-RNA Levels, Sero-biochemical Indices, and Clinicopathological Parameters in Patients with Hepatitis B Virus. Hepatitis Monthly 2024; 24(1) doi: 10.5812/hepatmon-145421
|
4 |
Ethem Ömeroğlu. The relationship between URG4 and clinicopathologic parameters and its effect on two-year survival in gastric carcinoma. Translational Oncology 2024; 50: 102122 doi: 10.1016/j.tranon.2024.102122
|
5 |
The oncogenic role of hepatitis B virus X gene in hepatocarcinogenesis: recent updates. Exploration of Targeted Anti-tumor Therapy 2024; 5(1): 120 doi: 10.37349/etat.2024.00209
|
6 |
Amirhossein Shahpar, Vahideh Hamidi Sofiani, Nazanin Zeinali Nezhad, Marzieh Charostad, Reza Ghaderi, Niloofar Farsiu, Amin Karimzadeh Kiskani, Sara Pezeshki, Mohsen Nakhaie. A narrative review: exploring viral-induced malignancies through the lens of dysregulated cellular metabolism and glucose transporters. BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-13013-y
|